Lagny sur Marne, France

Stanislas Didierlaurent


Average Co-Inventor Count = 3.6

ph-index = 2

Forward Citations = 38(Granted Patents)


Company Filing History:


Years Active: 1995-2005

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Stanislas Didierlaurent

Introduction

Stanislas Didierlaurent, an inventive mind based in Lagny sur Marne, France, has made significant contributions to the field of pharmaceuticals. With three patents to his name, his work primarily focuses on innovative antibiotic compounds that have potential applications in the medical industry.

Latest Patents

Didierlaurent's latest patents include groundbreaking discoveries such as "Uridine derivatives as antibiotics," which encompass all possible isomeric forms of a specific compound defined in the specification. These derivatives also include non-toxic, pharmaceutically acceptable salts that are useful as antibiotics. Another noteworthy patent is centered around "Acid pyrazole derivatives," detailing their preparation methods and their potential uses in various applications, particularly in medicine.

Career Highlights

Throughout his career, Stanislas Didierlaurent has worked with esteemed companies, including Roussel Uclaf and Aventis Pharma S.A. His experience in these organizations has aided in the development of his innovative pharmaceutical inventions, highlighting his expertise in the field.

Collaborations

Didierlaurent has collaborated with prominent professionals such as Jidong Zhang and Jean-Claude Caille. These partnerships have likely contributed to the refinement and success of his innovative concepts, emphasizing the importance of teamwork in scientific research and development.

Conclusion

Stanislas Didierlaurent stands out as a noteworthy inventor in the pharmaceutical sector. His patent portfolio not only showcases his innovative spirit but also his commitment to advancing antibiotic research. With continued collaboration and dedication, Didierlaurent's future contributions are anticipated to further benefit the medical community.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…